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q This review is intended as an Introduction to t
Protein Domains.
E-mail address: pdnash.uchicago@gmail.comThe serendipitous discovery of the SH2 domain unleashed a sea-change in our conceptual molecular
understanding of protein function. The reductionist approaches that followed from the recognition
of modular protein interaction domains transformed our understanding of cellular signal transduc-
tion systems, how they evolve and how they may be manipulated. We now recognize thousands of
conserved protein modules – many of which have been described in structure and function, impli-
cated in disease, or underlie targeted therapeutics. The reductionist study of isolated protein mod-
ules has enabled the reconstruction of the protein interaction networks that underlie cellular
signalling. Protein modules themselves are becoming tools to probe cellular activation states and
identify key interactions hubs in both normal and diseased cells and the concept of protein modu-
larity is central to the ﬁeld of synthetic biology. This brief word of introduction serves to highlight
the historical impact of the very powerful idea of protein modules and sets the stage for the exciting
on-going discoveries discussed in this issue.
2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. The SH2 domain that started it all
The early 1980’s witnessed an explosion in our understanding
of cellular signaling that ﬂowed from the discovery of tyrosine
phosphorylation [1] and the implication of tyrosine kinases in
transformation, growth and proliferation [2–5]. Yet the means by
which tyrosine kinase exert their effects and how different recep-
tors maintain speciﬁcity remained ambiguous. Transphosphoryla-
tion of kinases as a means of activation was well established but
the search for downstream targets produced the surprising result
that the most abundantly Tyr-phosphorylated protein in growth
factor stimulated cells is commonly the receptor itself. To Tony
Pawson and co-workers this ‘‘suggested that tyrosine phosphoryla-
tion might have unsuspected biochemical properties, and that the
kinases might have ways of recruiting their targets in addition to
the transient binding of a substrate to the active site of the en-
zyme’’ [6]. The pursuit of this idea lead to the identiﬁcation of
the Src homology 2 (SH2) domain as an independently folding do-
main of certain non-receptor tyrosine kinases that regulated kinase
activity [7–9]. In 1988, Tony Pawson wrote suggesting that signal-
ing by modular interactions might be a more general principle [10].
This principle was further expanded by the pioneering work ofal Societies. Published by Elsevier
he Special Issue on ModularHidesaburo Hanafusa and Bruce Mayer who cloned the Crk adaptor
protein composed exclusively of an SH2 domain and a second non-
catalytic domain termed the SH3 domain. Isolated SH2 domains
were found to bind to tyrosine-phosphorylated proteins and
directly able to interact with phosphotyrosine (pTyr) sites
[11–15]). The ﬁrst structural description of an SH2 domain re-
vealed how it recognizes the pTyr moiety of a phosphopeptide
and brought to light several features that are now recognized as
common themes of modular interaction domains [16].
The SH2 domain has its N- and C-termini juxtaposed in space
and removed from the ligand-binding face so that it may plug into
an existing polypeptide without necessarily perturbing the
surrounding structure. This feature of many modular domains
suggests an evolutionary mechanism for their rapid expansion
and deployment into novel proteins may help explain the develop-
ment of the varied array of SH2 domain proteins in the Unikont
branch of the Eukaryotes [17]. While domains have expanded in
various ways in different lineages, the undeniable power of inde-
pendently folding functional subdomains can be seen in the obser-
vation that most proteins encoded in the human genome contain
one or more identiﬁable domains [18].
2. Selectivity of interactions
The extent of SH2 domain binding speciﬁcity became evident
with early proteomic approaches using degenerate peptideB.V. Open access under CC BY-NC-ND license. 
P.D. Nash / FEBS Letters 586 (2012) 2572–2574 2573libraries [19]. Most SH2 domains recognize residues C-terminal to
the pTyr in a manner that varies from one domain to another and
that allows general classiﬁcation of SH2 domain binding motifs.
Binding motifs identiﬁed in vitro using peptide libraries reliably
mirror SH2 domain binding sites in vivo [20]. This opened the door
to an extensive array of reductionist biochemical and proteomic
studies to describe domain function and to the bioinformatic pre-
diction of modular protein–protein interactions [21]. In this issue,
Reimand et al. discuss the state of the art in predicting interaction
networks formed around peptide recognition modules. Structural
studies identiﬁed a highly conserved binding pocket for the pTyr
residue in which the phosphate is coordinated by an invariant argi-
nine residue in the SH2 domain. A second, more variable binding
surface, engages residues C-terminal to the pTyr and thereby
accommodates selectivity for speciﬁc peptide motifs [22,23]. The
concept of primary and secondary binding contacts has proven
paradigmatic of other families of protein interaction domains
(PIDs) that bind to a conserved peptide element while achieving
speciﬁcity through the variable recognition of ﬂanking residues.
Thus most SH2 domains recognize pTyr, many SH3 domains recog-
nize PXXP, and a number of FHA domains recognize phosphothre-
onine etc., while individual domain selectively is dictated by the
recognition of surrounding residues [24–26]. Later in this issue,
Joan Teyra and co-workers discuss the use of phage display to
map selectivity of PDZ and SH3 domains while David Gfeller dis-
cusses the speciﬁcity landscapes of peptide recognition modules.
In peptide library screens of SH2 domains it was apparent that
both permissive and disfavoured or non-permissive residues con-
tributed to binding motifs [19,20]. This feature turns out to be crit-
ical to developing selective interactions as many SH2 domains
share a preference for general motifs and anti-motif information
can deﬁne distinct subsets of ligands bound by one and not another
[27]. The concept of the language of peptides read by SH2 domains
is the subject of the review by Liu and Nash in this issue, while Ylva
Ivarsson discusses the plasticity of PDZ domain interactions and
how this versatile domain can be regulated in various ways. Kalle
Saksela and Perttu Permi present a review of SH3 domain speciﬁc-
ity with a focus on non-consensus binding events while Simin Ra-
highi and Ivan Dikic discuss selectivity of ubiquitin-binding
modules.
3. Reconstructing networks at a systems level
The ability to analyse domains in vitro to understand their
structure and function and then to reliably apply this knowledge
back to infer function in intact proteins and their role in signalling
networks has been a deﬁning feature of the incredibly powerful
reductionist approach. Over and over again the insights gained
from studying isolated components have informed and expanded
our understanding of otherwise inaccessibly complex cellular sys-
tems. The relevancy of the reductionist approach to study PIDs has
been proven time and again in their ability to explain in vivo
behavior of proteins, signal transduction networks and even phys-
iological behavior of cells and systems. Given the complex issues
associated with more ‘‘physiological’’ experiments, it is not surpris-
ing that much of our mechanistic understanding of protein–protein
interactions is based upon reductionist approaches and that both
the design and interpretation of cell-based experiments commonly
relies upon prior in vitro studies of the component parts. From de-
tailed studies of individual proteins to large-scale analysis of inter-
action speciﬁcity, reductionist approaches based on the concept of
modular protein interaction domains form the basis of much of
modern biochemistry, molecular and cellular biology. Volkmer
et al. detail the use of synthetic peptide arrays for the investigation
of protein interaction domains in this issue while Elisabeth LeRumeur and co-workers summarize the many uses of spectrin re-
peat domains. Modular interaction domains are now proving
invaluable tools for probing cellular activation states. Jadwin
et al. extend this concept to deﬁne ‘‘domainomics’’ and the variety
of proteomic approaches that draw upon the concept of modular
interaction domains and their deﬁned ligand motifs. Domains are
also useful reagents in proteomic studies as well as in the interpre-
tation of proteomic data. Anne-Claude Gingras and Brian Raught
present an update on the use of quantitative mass spectrometry
to reconstruct protein–protein interactions and networks.
4. Domains in human disease
SH2 domains and tyrosine kinases co-evolved [17] and display
remarkable synergy. This can inform therapeutic development
and our understanding of drug action. The kinase inhibitor Imati-
nib (Gleevec) selectively recognizes a conformation of the autoin-
hibited Abl catalytic domain that is imposed by the adjacent SH2
domain [28]. An engineered Abl SH2-binding ﬁbronectin type III
monobody that disrupts the SH2 domain-kinase interface inhibits
Bcr–Abl kinase activity and induces apoptosis in CML cells [29].
Disruption of the SH2-kinase interface also increases sensitivity
of imatinib-resistant Bcr-Abl mutants to a range of tyrosine kinase
inhibitors [29].
While a number of SH2 domain inhibitors have been developed,
none are thus far clinically successful. Yet the concept of develop-
ing inhibitors of protein–protein interactions that target modular
interaction domains is now gaining traction. Members of the Bcl-
2 family are composed of Bcl-2 homology (BH) domains, which
come in four ﬂavours (BH1–4). The Bcl-2 family of proteins bind
to pro-apoptotic terminal effector proteins Bax and Bak and in
doing so block the intrinsic apoptotic pathway. Activated stress
pathways disrupt these restraints by BH3-only proteins (e.g. Bad,
Bim, etc.), which competitively displace Bcl-2-like proteins and
thus release Bax or Bak to form homo-oligomeric pores in the
mitochondrial membranes and initiate apoptosis. Inhibitors devel-
oped to mimic BH3 domain interactions with Bcl-2 family disrupt
the protective effects of Bcl-2 family and induce apoptosis of cells
via the intrinsic pathway [30]. So-called BH3-mimetics are small
molecules developed to utilize multiple binding peptide-binding
contacts that are broadly analogous to the multiple contact regions
on many protein interaction domains. Several putative BH3-
mimetics have been extensively characterised and are undergoing
clinical evaluation [31]. These compounds clearly show the poten-
tial for developing effective and speciﬁc inhibitors of protein–pro-
tein interaction domains. The trick to developing such compounds
has been a move away from simple screening of small molecule li-
braries of limited diversity and instead relies on a semi-rational ap-
proach of using nuclear magnetic resonance (NMR)-based
screening, parallel synthesis and structure-based design [32]. In
principle, this approach may be effective for many protein interac-
tion domains that utilize multiple low-afﬁnity contacts and may be
ﬁne-tuned to be highly selective using mimics of non-permissive
residues to block off-target effects.
Eric Haura discusses SH2 domains as markers for normal or per-
turbed signalling networks and the potential use of such data to
predict therapeutic response and tailor therapies for personalized
medicine. Marius Sudol and co-workers discuss the WW domain
of the Golabi-Ito-Hall Syndrome Protein PQBP1 and how a point
mutation in theWWdomain results in loss of binding function that
underlies some cases of X chromosome-linked intellectual disabil-
ity disorder. Panagis Filippakopoulos and Stefan Knapp discuss the
Bromo-domain that recognizes acetyl-lysine and present new
targets for the development of speciﬁc protein interaction
inhibitors.
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The emerging ﬁeld of synthetic biology builds extensively on the
foundation that proteins are modular and that protein interaction
domains can be swapped into novel polypeptideswhilemaintaining
their native conformation and activity. Early work on the modular
interaction domains such as SH2 and SH3 laid the groundwork for
much ofmodern synthetic biology. Pawson and co-workers showed
that single residue alterations in the speciﬁcity pocket of an SH2 do-
main can not only change the binding properties of the domain
in vitro but also it’s biological activity in an intact organism [33]
and that the fusion of the SH2 domain of adaptor proteins to a death
effector domain of the FADD adaptor rerouted mitogenic growth
factor signalling to induce caspase activation and cell death [34].
Such chimeric adaptors could be used to selectively kill oncogenic
cells in which RTK activity is deregulated, suggesting the potential
for rewiring cancer cells using synthetic biology approaches as a
means of therapy. The concept of interrogating biology by recon-
structing constituent components and rearranging networks is
proving a powerful tool to unravel the organizing principals or net-
works and signalling systems (reviewedby [35]). Indeed, our under-
standing of networks and network evolution continues to come
from studying deﬁned protein interaction domains such as SH3 do-
mains [36]. In this issue Marc Lewitzkey et al. discuss the molecular
architecture of complexes and networks. Klaus Scheffzek and Stefan
Welti summarize the PH domain while Catherine Qiurong Pan and
Boon Chuan Low discuss the BCH domain. Raymond Birge delves
into the C-terminal SH3 domain of Crk and it’s binding and regula-
tion. Going forward, the reductionist approaches that have followed
from a modular understanding of protein architecture continue to
illuminate our mechanistic understanding of cellular processes.
Sachdev Sidhu makes a compelling case for a next iteration afﬁnity
reagent technology and a goal of developing genome-wide afﬁnity
reagents. Bruce Mayer provides a glimpse of dynamic protein
interactions as signal transduction unfold in live cells and Gianni
Cesareni and co-workers describe the human phosphatase interac-
tome. Studies of increasing scale, systems level analysis and deep
understanding of the mechanisms by which dynamic protein inter-
actions guide cellular behaviour continue to challenge and enlight-
en our understanding of modular protein interaction domains.
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